Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 618 participants.
Also called NCT04834089
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 618 participants
- Sponsor
- Butantan Institute
- Registry
-
NCT04834089
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Brazil
- Registry status
- Unknown status
Technical summary
Registry record NCT04834089. Randomized; double masking; primary purpose treatment. Start 2021-05 (anticipated); primary completion 2022-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases
- Acronym
- SOROCOV
- Condition
- Immunosuppression
- Condition
- Cancer
- Condition
- COVID-19
- Condition
- Other Complication of Kidney Transplant
- Condition
- Chemotherapy
- Condition
- Renal Disease
- Condition
- Diabetes Mellitus
- Condition
- Cardiovascular Diseases
- Condition
- Chronic Obstructive Pulmonary Disease
- Intervention (Biological)
- AntiSARS-CoV-2 Serum
- Intervention (Other)
- Placebo
- Lead sponsor
- Butantan Institute
Record details
- Record id
cardio:ct-nct04834089- Content hash
a355ab42dc681c70f1c267b660917396859f7fe6b2d4f8a2fbffdee0f51b6f8a